Breakthrough trial tests immune treatment for mysterious childhood brain disorder
NCT ID NCT04508530
Summary
This Phase 3 study tested whether Panzyga (an intravenous immunoglobulin treatment) works better than a placebo for children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS). The trial involved 71 children and teenagers aged 6-17 who suddenly developed severe obsessive-compulsive behaviors and other neuropsychiatric symptoms. Researchers measured changes in symptoms over 9 weeks to see if the immune-based treatment provided meaningful relief.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Octapharma Research Site
Tucson, Arizona, 85712, United States
-
Octapharma Research Site
Little Rock, Arkansas, 72202, United States
-
Octapharma Research Site
Los Angeles, California, 90024, United States
-
Octapharma Research Site
Palo Alto, California, 94305, United States
-
Octapharma Research Site
Centennial, Colorado, 80112, United States
-
Octapharma Research Site
Boston, Massachusetts, 02114, United States
-
Octapharma Research Site
Lebanon, New Hampshire, 03756, United States
-
Octapharma Research Site
Genova, 16147, Italy
-
Octapharma Research Site
Roma, 00161, Italy
-
Octapharma Research Site
Roma, 00186, Italy
-
Octapharma Research Site
Gothenburg, 41685, Sweden
-
Octapharma Research Site
Stockholm, 17164, Sweden
Conditions
Explore the condition pages connected to this study.